Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 226-408-0 | CAS number: 5395-50-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2001
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 001
- Report date:
- 2002
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 1995
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- Tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione
- EC Number:
- 226-408-0
- EC Name:
- Tetrahydro-1,3,4,6-tetrakis(hydroxymethyl)imidazo[4,5-d]imidazole-2,5(1H,3H)-dione
- Cas Number:
- 5395-50-6
- Molecular formula:
- C8H14N4O6
- IUPAC Name:
- 1,3,4,6-tetrakis(hydroxymethyl)-octahydro-[1,3]diazolo[4,5-d]imidazole-2,5-dione
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: BASF AG; Batch No. 0767
- Expiration date of the lot/batch: March 2002
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Stored at < 25°C, in die dark
- Stability of the test substance in the solvent/vehicle: The analysis of the formaldehyde content in the test substance revealed negligible loss for a period of 4 hours.
FORM AS APPLIED IN THE TEST: dissolved in distilled water; dose solution was prepared daily prior to dosing
Test animals
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- The rat was selected as a test system because it is a readily available laboratory rodent. species. lt has been historically shown to be a suitable model for repeated dose toxicity assessment and is recommended by the OECD and other regulatory authorities.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Jai Research Foundation, Valvada - 3 96 108, Dist. Valsad, Gujarat, India
- Females nulliparous and non-pregnant: yes
- Age at study initiation: about 7 weeks
- Fasting period before study: not specified
- Weight at start of treatment: males: 118 - 158 g; females: 95 - 130 g
- Housing: individually; during acclimation period 5/cage
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 5 days
DETAILS OF FOOD AND WATER QUALITY:
Every new batch of feed used was analysed or microbial contaminants. Rat pellet feed and drinking water were analysed for potential contaminants once in six months.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 - 24°C
- Humidity (%): 67% (mean)
- Photoperiod (hrs dark / hrs light): 12 / 12
IN-LIFE DATES: From: June 16, 2001 To: July 20 / August 03, 2001
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- The oral administration represents a possible route of human exposure.
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
Required quantities of test substance were dissolved in distilled water to get the desired dose solutions with appropriate concentrations for various treatment groups. Dose solution was prepared daily just prior to dosing. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Purity of formaldehyde content in the test substance in dose solution was detected by the folowing procedure:
A volume of 1 ml samnple was pipetted out and diluted to 100 ml with distilled water. A volume of 100 ml diluted sample was placed in different distillation apparatus with the addition of 85% phosphoric acid (15 ml)
and distilled out. A series of standard solutions was pipetted out from 10 ml standard solutions, i. e., 0.25, 0.5, 1.0, 1.5, 2.0 ml in to 25 ml of volumetric flask with addition of10 ml of reagent solution and volume was made with distilled water (concentration of standard solutions were 1 ppm , 2 ppm, 4 ppm, 6 ppm, 8 ppm). A volume of 1.0 ml of the above distilled solution was pipetted out into a 25 ml volumetric flask with the addition of 10 ml of antona reagent and volume was adjusted with distilled water. Then standard and sample flasks were kept for 3.0 minutes in a water bath at 40°C and was cooled down at 20°C. The Blank solution was prepared with distilled water using the same procedure. Above prepared standard and sample solution was again diluted to 5 times with distilled water. The absorbance of the diluted standard and sample was measured against die blank at 412 nm. - Duration of treatment / exposure:
- 28 days; recovery group animals were kept under observation for further 14 days
- Frequency of treatment:
- once daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Remarks:
- Low dose
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Remarks:
- Mid dose
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- High dose
- No. of animals per sex per dose:
- 5; 3 males and females in one additonal control and high dose group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: In order to find out die irritancy, if any, of the test substance at the dose level of 1000 mg/kg body weight two additional groups of animals i. e., one control and one high dose, each consisting of 3 males and 3 females, were included in die 28 day study and dosed
for a period of 14 days. On the 15th day these animals were subjected to a complete gross pathology examination which showed no treatment related irritation in the gastrointestinal tract. Hence, the 28 day repeated dose oral toxicity study was performed at the same highest dose.
- Post-exposure recovery period in satellite groups: yes, 14 days
- Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: once a day; twice daily observation for morbidity and mortality
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once a day
BODY WEIGHT: Yes
- Time schedule for examinations: on the day of initiation of treatment and at weekly intervals thereafter
FOOD CONSUMPTION: Yes
- Time schedule for examinations: once a week
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: once before commencement of the treatment and prior to terminal sacrifice
- Dose groups that were examined: all animals
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at the end of the treatment and revovery period
- Anaesthetic used for blood collection: Yes; light ether anesthesia
- Animals fasted: Yes; overnight
- How many animals: all animals
- Parameters checked in table [No. 1] were examined.
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at the end of the treatment and revovery period
- Anaesthetic used for blood collection: Yes; light ether anesthesia
- Animals fasted: Yes; overnight
- How many animals: all animals
- Parameters checked in table [No. 1] were examined.
NEUROBEHAVIOURAL OBSERVATIONS: yes
- Time schedule: once before commencement of the treatment and at weekly intervals thereafter
- Battery of functions tested: posture, convulsions, ease of removal from the home cage, handling reactivity of the animal, autonomic signs such as palpebral closure, lacrimation, salivation and piloerection
- Open field observations (gait, monilty score, arousal level, vocalisations, rearing, respiration, clonic or tonic movements, urination and defecation, stereotypy, bizarre behaviour) - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes (see table no. 2)
HISTOPATHOLOGY: Yes; All the preserved organs (see table no. 2) from control and high dose groups as well as liver, kidneys, heart, spleen and lungs of all the animals - Statistics:
- Raw data were processed by the Department of Biostatistics and Systems Information, Jai Research Foundation to give group means and standard deviations with significance between the control and treated groups, using in-house developed statistical software. All the parameters characterised by continuous data such as rearing count, urination count, defecation, body weight, feed consumption, organ weight, relative organ weight, haematological and clinical chemnistry data were subjected to Bartlett's test to meet the homogeneity of variance before conducting Analysis of Variance (ANOVA) and Dunnett' s t-test. Where the data did not meet die homogeneity of variance, Student's t-test was performed to calculate significance.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- In high and mid dose males, the monocyte count was significantly enhanced. This effect was not observed at the end of the recovery phase.
Females of all dose groups showed an increase in mean corpuscular volume and an according decrease in measn corpuscular haemoglobin concentration. In the absence of any other alterations in the red blood corpuscle, these changes are considered biologically insignificant. - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Males: decreased sodium and potassion values mainly in the low dose animals were considered incidental
Females: Marginally, though statistically significantly increased phophorus values in mid and high dose animals without deviations in calcium levels and/or histopathological alterations in the kidney were considered biologically irrelevant. A statistical increase in total protein, though marginal and hardly dose related, in all dose groups was not considered adverse. All other changes occured with no relation to dose and were considered incidental. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Absolute prostate weights were increased in high dose recovery males, but not at the end ot the treatment period.
In females of the recovery group, the absolute spleen weight was decreased, and the relative liver weight was increased.
As for males, in the absence of histopathological correlates and since the changes were not observed at the end of the treatment period, they were considered as irrelevant and incidental. - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Degenerative or inflammatory changes were observed at similar incidence and severity in control and treated animals.
- Histopathological findings: neoplastic:
- no effects observed
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse effects observed
Target system / organ toxicity
- Critical effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Based on the results of this study, it is concluded that the No Observed Adverse Effect Level (NOAEL) of the test substance in Wistar rats exposed over a period of 28 days is 1000 mg/kg body weight.
- Executive summary:
This study was conducted to assess the toxic effects of the test substance to rats, when administered orally by gavage for 28 consecutive days according to OECD 407. Three groups of Wistar rats comprising 5 males and 5 females per group with the test substance at 100 (low dose), 300 (mid dose) and 1000 (high dose) mg/kg b.wt. A concurrent control group comprising die same number of animals was also maintained in die study. In addition, a high dose recovery (1000 mg/kg b. wt.) and a control recovery group were included in the study to investigate the persistence, recovery or delayed effect of the test substance for an other period of 14 days.
Each rat was observed for visible signs of reactions to the treatment once a day and for rnortality and morbidity twice a day. Individual body weight and feed consumption were monitored weekly. Detailed clinical examination/neurobehavioural observations were conducted for each animal once prior to initiation of treatment and at weely intervals thereafter. Ophthalmological exanmination was conducted on all animals prior to treatment and prior to sacrifice. Haematological observations and biochemical analysis of blood samples were performed on all animals at the end of treatment and recovery periods. All the rats were sacrificed and subjected to a gross pathological examination at the end of treatment and recovery period. Absolute organ weights were recorded and relative organ weights were calculated for die organs viz., adrenal, testes/ovaries, epididymis/uterus, posate, kidneys, brain, heart, spleen, liver and thymus in all rats. Histopathological examination was made on all preserved organs from control and high dose group animals as well as liver, kidneys, spleen, heart and lungs of all animals.
No treatment related mortality or visible clinical symptoms were observed in any of the treatment group aimals. Body weight, feed consumption and opthalmological examination did not reveal treatmnent related alterations.
The test substance did not alter the neurobehavioural pattern of animals.
Haematology parameters studied in treated males were comparable to control group except in monocyte count; significantly increased monocyte count was observed in mid and high dose groups.
The clinical chemistry parameters did not reveal any major alterations in treated males. In female increased total protein in all the dose groups (low, mid and high dose) and phosphorus in mid and high dose groups were observed. All other parameters studied were comparable to control group.
No treatment related changes were observed in the absolute organ weight and relative organ weight of treated groups as compared to control groups.
Gross pathology examination did not reveal any treatment related lesions.
The histopathological examination of various organs /tissues from control and high dose (1000 mg/kg b. wt.) group animals did not reveal any treatment related effect.
Based on the results of this study, the No Observed Adverse Effect Level (NOAEL) of the test substance in Wistar rats exposed for a period of 28 days is 1000 mg/kg b. wt.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.